Prevention of advanced colorectal cancer by screening using the immunochemical faecal occult blood test: A case-control study

British Journal of Cancer

Volumn 89, Issue 1, 2003, Pages 23-28

  Nakajima, M ^a   Saito, H ^a,b   Soma, Y ^a   Sobue, T ^c   Tanaka, M ^a   Munakata, A ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Advanced cancer; Case control study; Colorectal cancer; Faecal occult blood; Immunochemical test; Screening

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INVASION; CANCER PREVENTION; CANCER SCREENING; CASE CONTROL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PRIORITY JOURNAL; RECTUM CANCER; RISK ASSESSMENT;

ADULT; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOCHEMISTRY; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; OCCULT BLOOD; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0042847062     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601002     Document Type: Article

References (35)

1. Allison JE, Tekawa IS, Ransom LJ, Adrain AL (1996) A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 334: 155-159
2. Castiglione G, Zappa M, Grazzini G, Mazzotta A, Biagini M, Salvadori P, Ciatto S (1996) Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer 74: 141-144
3. Clark EA, Anderson TW (1979) Does screening by 'Pap' smears help prevent cervical cancer? Lancet 2: 1-4
4. Cole P, Morrison AS (1980) Basic issues in population screening for cancer. J Natl Cancer Inst 64: 1263-1272
5. Dunn JE, Schweitzer V (1981) The relationship of cervical cytology to the incidence of invasive cervical cancer and mortality in Alameda County, California, 1960 to 1974. Am J Obstet Gynecol 139: 868-876
6. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, Jame PD, Mangham CM (1996) Randomized controlled trial of fecal-occult-blood screening for colorectal cancer. Lancet 348: 1472-1477
7. Hiwatashi N, Morimoto T, Fukao A, Sato H, Sugahara N, Hisamichi S, Toyota T (1993) An evaluation of mass screening using fecal occult blood test for colorectal cancer in Japan: a case-control study. Jpn J Cancer Res 84: 1110-1112
8. Iwase T (1992) The evaluation of an immunochemical fecal occult blood test by reversed passive hemagglutination compared with Hemoccult II in screening for colorectal cancer. In Fecal Occult Blood Tests: Current Issues and New Tests, Young GP, Saito H (eds) pp 90-95. SmithKline Diagnostics Inc: San Jose
9. Japanese Society for Cancer of the Colon and Rectum (1998) General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus, 6th edn, p p 37-42. Tokyo: Kanehara & Co Ltd
10. Kern SE, Fearon ER, Tersmette KWF, Enterline JP, Leppert M, Nakamura Y, White R, Vogelstein B, Hamilton SR (1989) Allelic loss in colorectal carcinoma. JAMA 261: 3099-3103
11. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O (1996) Randomized study of screening for colorectal cancer with faecal occult blood test. Lancet 348: 1467-1471
12. Macgregor E, Moss SM, Parkin MD, Day NE (1985) A case-control study of cervical cancer screening in north east Scotland. Br Med J 290: 1543-1546
13. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman M, Ederer F (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328: 1365-1371
14. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM (2000) The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343: 1603-1607
15. Mandel JS, Church TR, Ederer F, Bond JH (1999) Colorectal cancer mortality effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91: 434-437
16. Morrison AS (1992) Screening in Chronic Disease, 2nd edn, pp 3-20. New York: Oxford University Press
17. O'Brien MJ, Winawer SJ, Zauber AG, Gottlieb LS, Sternberg SS, Diaz B, Dickersin GR, Ewing S, Geller S, Kasimian D, Komorowski R, Szporn A, and The National Polyp Study Workgroup (1990) The national polyp study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 98: 371-379
18. Petrelli N, Michalek AM, Freedman A, Baroni M, Rodriguez-Bigas M (1994) Immunochemical versus guaiac occult blood stool tests: results of a community- based screening program. Surg Oncol 3: 27-36
19. Rhodes JM (2000) Colorectal cancer screening in the UK: joint position statement by the British Society of Gastroenterology, the Royal College of Physicians, and the Association of Coloproctology of Great Britain and Ireland. Gut 46: 746-748
20. Saito H (1996) Screening for colorectal cancer by immunochemical fecal occult blood testing. Jpn J Cancer Res 87: 1011-1024
21. Saito H, Soma Y, Koeda J, Wada T, Kawaguchi H, Sobue T, Aisawa T, Yoshida Y (1995) Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer 61: 465-469
22. Saito H, Soma Y, Nakajima M, Koeda J, Kawaguchi H, Kakizaki R, Chiba R, Aisawa T, Munakata A (2000) A case-control study evaluating occult blood screening for colorectal cancer with Hemoccult test and an immunochemical hemagglutination test. Oncol Rep 7: 815-819
23. Saito H, Tsuchida S, Kakizaki R, Fukushi M, Sano M, Aisawa T, Munakata A, Yoshida Y (1984) Immunochemical fecal occult blood test for mass screening of colorectal cancer by reversed passive hemagglutination (RPHA) (rapid communication). Jpn J Gastroenterol 81: 2831 (in Japanese).
24. Saito H, Yoshida Y (1996) Mass screening-Japanese perspective. In Prevention and Early Detection of Colorectal Cancer: Principles and Practice, Young GP, Rozen P, Levin B (eds). London: WB Saunders
25. Sasco AJ, Day NE, Stephen DW (1986) Case-control studies for the evaluation of screening. J Chron Dis 39: 399-405
26. Schottenfeld D, Winawer SJ (1996) Cancers of the large intestine. In Cancer Epidemiology and Prevention, Schottenfeld D, Fraumeni Jr JF (eds) 2nd edn, pp 813-840. New York: Oxford University Press
27. Sobin LH, Wittekind Ch (1997) TNM Classification of Malignant Tumors, 5th edn, pp 66-69. Geneva: Wiley Liss
28. St John DJB, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson AM, Macrae FA, Penfold JCB (1993) Evaluation of new occult blood test for detection of colorectal neoplasm. Gastroenterology 104: 1661-1668
29. St John DJB, Young GP, McHutchinson JG, Deacon MC, Alexeyeff MA (1992) Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasm. Ann Intern Med 117: 376-382
30. Van der Graaf Y, Zielhuis G, Peer PGM, Vooijs PG (1988) The effectiveness of cervical screening: a population-based case-control study. J Clin Epidemiol 41: 21-26
31. Wada T, Saito H, Soma Y, Koeda J, Kawaguchi H, Tanaka M, Yoshida Y, Munakata A (1996) Survival benefit for patients with colorectal cancer detected by population-based screening program using an immunochemical fecal occult blood test. Int J Oncol 9: 685-691
32. Young GP, St John DJB (1992) Fecal occult blood tests: choice, usage and clinical applications. Clin Biochem Rev 13: 161-167
33. Young GP, St John DJB, Winawer SJ, Rozen P (2002) Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies. Am J Gastroenterol 197: 2499-2507
34. Zappa M, Castiglione G, Grazzini G, Falini P, Giorgi D, Paci E, Ciatto S (1997) Effect of fecal occult blood testing on colorectal mortality: results of a population-based case-control study in the district of Florence, Italy. Int J Cancer 73: 208-210
35. Zappa M, Castiglione G, Paci E, Grazzini G, Rubeca T, Turco P, Crocetti E, Ciatto S (2001) Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: the district of Florence experience. Int J Cancer 92: 151-154